Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D

Area of Science:

• Biopharmaceutical Development
• Drug Manufacturing
• Cost Analysis

Background:

• Biopharmaceutical R&D is costly, with process development and manufacturing being significant components.
• Accurate cost modeling is crucial for effective portfolio management and strategic decision-making.
• Understanding cost drivers is essential for optimizing resource allocation throughout the drug development lifecycle.

Purpose of the Study:

• To benchmark and analyze process development and manufacturing costs within the biopharmaceutical drug development cycle.
• To quantify the contribution of these costs to overall research and development (R&D) expenditure.
• To assess the impact of varying clinical success rates on manufacturing budgets.

Main Methods:

• Development of a biopharmaceutical drug development lifecycle cost model.
• Inclusion of costs, durations, risks, and interdependencies of key development activities.
• Estimation of process development and manufacturing budgets required for market success at each phase.

Main Results:

• Process development and manufacturing costs are predicted to be ~$60M (early phase) and ~$70M (late phase) for a ~12% clinical success rate.
• For lower success rates (~4%), these costs escalate to ~$190M (early phase) and ~$140M (late phase), a 2.5-fold increase.
• Process development and manufacturing costs per market success are estimated to be 13-17% of the total R&D budget.

Conclusions:

• Process development and manufacturing budgets must be carefully planned considering potential clinical attrition rates.
• The study provides a quantitative framework to support strategic decision-making in biopharmaceutical portfolio management.
• Cost-effective strategies for process development and manufacturing are critical for R&D investment optimization.